REPL - Replimune Group, Inc. Debt to Book Capitalization Ratio

This chart of the market valuation for Replimune Group, Inc. (REPL) is based on the 1.14 metric. The business relies on modified viruses that attack tumors, expanding the patient pool through new diagnoses pending an FDA verdict. Replimune Group, Inc. (REPL) acts as a leader in developing targeted cancer eradication tools, leveraging a powerful R&D base. However, global conflicts are hindering biomaterial logistics and disrupting clinical trial timelines.

REPL Replimune Group, Inc.: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for Replimune Group Inc (REPL)

- price and consensus price forecast:

Stock Price Replimune Group, Inc.|REPL - Consensus Target

- market capitalization data:

Market Value Replimune Inc.|REPL - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Replimune|REPL - Company Book Value|Market Value to Book Value Ratio replimune.com|REPL - Company Assets

- debt and liquidity data:

Total Debt to Capital Replimune Group, Inc.|REPL - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Replimune Corp|REPL - Company Cumulative Debt|Debt to Book Value Replimune Inc.

Analysis of all company metrics:REPL, Replimune Group, Inc.

Replimune Group, Inc. (REPL) develops innovative oncolytic viruses based on the RPx platform for the selective destruction of tumors and the activation of the immune response. By analyzing the trajectory of the company's financial leverage on GURU.Markets, an investor assesses the ratio of borrowed funds to the market value of equity, which allows for the identification of asset undervaluation or the risk of business overheating when preparing for a potential acquisition.

Competitors of Replimune Group, Inc.